title: Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial.
authors.forename: George
authors.initials: G
authors.lastname: Somlo
authors.forename: Ashkan
authors.initials: A
authors.lastname: Lashkari
authors.forename: William
authors.initials: W
authors.lastname: Bellamy
authors.forename: Todd M
authors.initials: TM
authors.lastname: Zimmerman
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Tuscano
authors.forename: Margaret R
authors.initials: MR
authors.lastname: O'Donnell
authors.forename: Ann F
authors.initials: AF
authors.lastname: Mohrbacher
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Forman
authors.forename: Paul
authors.initials: P
authors.lastname: Frankel
authors.forename: Helen X
authors.initials: HX
authors.lastname: Chen
authors.forename: James H
authors.initials: JH
authors.lastname: Doroshow
authors.forename: David R
authors.initials: DR
authors.lastname: Gandara
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D012008:Recurrence; D013792:Thalidomide / Q000008:administration & dosage; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D013792:Thalidomide